British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005

Br J Dermatol. 2005 Sep;153(3):486-97. doi: 10.1111/j.1365-2133.2005.06893.x.
No abstract available

Publication types

  • Guideline
  • Practice Guideline

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • CD11 Antigens / immunology
  • Etanercept
  • Humans
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G / therapeutic use
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use*
  • Patient Selection*
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Remission Induction
  • Risk
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CD11 Antigens
  • Immunoglobulin G
  • Immunologic Factors
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Etanercept
  • efalizumab